# Table 3 Survival times and progression times between cTACE and DEB-TACE treatments

Variables cTACE DEB-TACE p-value
Total (n = 201) (n = 72)
Survival status    0.045
Died within ≤5 years follow-up 153 (76.1) 48 (66.7)
Died after more than 5 years follow-up 10 (5.0) 1 (1.4)
Survived until last follow-up 38 (18.9) 23 (31.9)
Progression status    0.218
Progression 192 (95.5) 66 (91.7)
Loss of follow-up/censored 9 (4.5) 6 (8.3)
Survival time, months 37 (32.2, 41.8) 37 (23.5, 50.5) 0.091
Progression time, months 11.0 (9.6, 12.4) 16.0 (13.1, 18.9) 0.019
BCLC stage = A (n = 73) (n = 16)
Survival status    0.083
Died within ≤5 years follow-up 57 (78.1) 9 (56.3)
Died after more than 5 years follow-up 3 (4.1) 0 (0)
Survived until last follow-up 13 (17.8) 7 (43.8)
Progression status    0.219
Progression 70 (95.9) 14 (87.5)
Loss of follow-up/censored 3 (4.1) 2 (12.5)
Survival time, months 42 (36.1, 47.9) 45 (0, 90.1) 0.149
Progression time, months 12 (10.5, 13.5) 19 (17.8, 20.2) 0.217
BCLC stage = B + C (n = 128) (n = 56)
Survival status    0.270
Died within ≤5 years follow-up 96 (75) 39 (69.6)
Died after more than 5 years follow-up 7 (5.5) 1 (1.8)
Survived until last follow-up 25 (19.5) 16 (28.6)
Progression status    0.495
Progression 122 (95.3) 52 (92.9)
Loss of follow-up/censored 6 (4.7) 4 (7.1)
Survival time, months 33 (27.1, 38.9) 36 (21.3, 50.7) 0.191
Progression time, months 10 (8.1, 11.9) 15 (12.4, 17.7) 0.032
1. Survival and progression status are summarized as n (%) by treatment; Survival time- and progression time-related data are summarized as median (95%CI) by treatment
2. Differences between treatments were compared using Pearson Chi-square test / or Fisher’s exact test for survival and progression status and Log-rank test for survival time or progression time
3. Bold p-values indicate statistical significance (p < 0.05)